Results 101 to 108 of about 59,455 (108)

TheChlamydia trachomatissecreted effector protein CT181 binds to Mcl-1 to prolong neutrophil survival

Faris R, Koch R, McCaslin P, Challagundla N, Steiert B, Andersen SE, Smith P, Jabeena C, Yau P, Rudel T, Weber MM.   +10 more
europepmc   +1 more source

Post-exposure vaccine protection of CTH522/CAF^®01 against reinfection with Chlamydia trachomatis requires Th1/Th17 but not Th2-immunity. [PDF]

NPJ Vaccines
Nguyen NDNT, Subratheepam S, Guleed S, Melchiors KM, Olsen AW, Wørzner K, Follmann F, Dietrich J.   +7 more
europepmc   +1 more source

Structural Elucidation of the Reduced Mn(III)/Fe(III) Intermediate of the Radical-Initiating Metallocofactor in <i>Chlamydia trachomatis</i> Ribonucleotide Reductase. [PDF]

Biochemistry
Martinie RJ, Livada J, Kothiya N, Bollinger JM, Krebs C, Silakov A.   +5 more
europepmc   +1 more source

Corrigendum: Editorial: Chlamydia trachomatis infection: epidemiology, prevention, clinical, and basic science research. [PDF]

Front Public Health
Li C, Ong J, Tang W, Wang C.
europepmc   +1 more source

Low-Frequency, Sustained CD4 T-Cell Responses Chlamydia trachomatis in Women: Predominant Targeting of Chlamydial Proteaselike Activity Factor (CPAF). [PDF]

J Infect Dis
Li Y, Warren JA, Poston TB, Clutton G, Shaw FR, Conrad SZ, Xu Y, Zheng X, Yount KS, O'Connell CM, Wiesenfeld HC, Darville T, Goonetilleke N.   +12 more
europepmc   +1 more source

Cervicovaginal inflammation and HIV target cell activation in adolescent girls and young women with asymptomaticChlamydia trachomatisinfections

Dabee S, Barnabas S, Kullin B, Versteeg B, Mkhize N, Muller E, Maseko V, Lewis DA, Dietrich J, Gray G, Gill K, Bekker L, Sinkala M, Martin DP, Bruisten SM, Jaspan HB, Passmore JS.   +16 more
europepmc   +1 more source